Normally, foreign investors acquire Israeli biotechs that develop cancer treatments. But here, Israel’s Redhill Biopharma has bought pancreatic cancer treatment RP101 from Germany’s RESprotect GmbH. RP101 has passed Phase II trials and has vital orphan status.
http://ir.redhillbio.com/releasedetail.cfm?ReleaseID=866033